FY2028 EPS Estimate for Kodiak Sciences Boosted by Analyst

Kodiak Sciences Inc. (NASDAQ:KOD) – Equities researchers at HC Wainwright boosted their FY2028 EPS estimates for shares of Kodiak Sciences in a report released on Monday, October 12th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings per share of ($0.97) for the year, up from their previous estimate of ($1.78). HC Wainwright has a “Buy” rating and a $126.00 price target on the stock. The consensus estimate for Kodiak Sciences’ current full-year earnings is ($3.97) per share. HC Wainwright also issued estimates for Kodiak Sciences’ FY2029 earnings at $2.19 EPS.

Kodiak Sciences (NASDAQ:KOD) last announced its earnings results on Thursday, August 13th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.09).

Other equities research analysts also recently issued research reports about the company. Weiss Ratings downgraded Kodiak Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, October 6th. UBS Group increased their target price on Kodiak Sciences from $80.00 to $120.00 and gave the stock a “buy” rating in a research note on Monday, September 28th. JPMorgan Chase & Co. raised their target price on Kodiak Sciences from $56.00 to $66.00 and gave the company an “overweight” rating in a report on Monday, August 3rd. The Goldman Sachs Group restated a “neutral” rating and set a $103.00 target price on shares of Kodiak Sciences in a report on Wednesday, September 30th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $112.00 target price on shares of Kodiak Sciences in a research report on Monday, September 28th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $104.71.

Kodiak Sciences Stock Down 7.7%

KOD opened at $91.63 on Wednesday. Kodiak Sciences has a 52 week low of $10.94 and a 52 week high of $104.00. The business has a fifty day simple moving average of $50.99 and a 200-day simple moving average of $43.35. The firm has a market cap of $5.76 billion, a P/E ratio of -21.87 and a beta of 2.03.

Hedge Funds Weigh In On Kodiak Sciences

Institutional investors have recently modified their holdings of the business. V Square Quantitative Management LLC purchased a new stake in Kodiak Sciences during the 1st quarter worth about $26,000. Westfuller Advisors LLC purchased a new position in shares of Kodiak Sciences in the 1st quarter valued at about $26,000. KBC Group NV purchased a new position in shares of Kodiak Sciences in the 1st quarter valued at about $39,000. EverSource Wealth Advisors LLC grew its position in shares of Kodiak Sciences by 94.5% during the first quarter. EverSource Wealth Advisors LLC now owns 1,927 shares of the company’s stock worth $73,000 after buying an additional 936 shares in the last quarter. Finally, E Fund Management Co. Ltd. acquired a new position in shares of Kodiak Sciences during the second quarter worth about $228,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Insider Transactions at Kodiak Sciences

In other Kodiak Sciences news, Director Bros. Advisors Lp Baker bought 33,726 shares of Kodiak Sciences stock in a transaction on Tuesday, September 29th. The shares were bought at an average cost of $85.05 per share, for a total transaction of $2,868,396.30. Following the acquisition, the director directly owned 20,191,214 shares in the company, valued at $1,717,262,750.70. This represents a 0.17% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last quarter, insiders have purchased 1,941,755 shares of company stock worth $156,986,026. 44.40% of the stock is owned by corporate insiders.

About Kodiak Sciences

Kodiak Sciences Inc (NASDAQ: KOD) is a clinical-stage biopharmaceutical company focused on developing medicines for serious retinal diseases. The company’s research is centered on its Antibody Biopolymer Conjugate (ABC) platform, which is designed to combine antibody-based therapies with biopolymer technology to potentially extend the duration of treatment in the eye.

Kodiak’s lead programs have focused on ophthalmic diseases involving abnormal blood-vessel growth or leakage, including wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion.